Direct-to-consumer virtual care company Hims & Hers is partnering with Novo Nordisk to allow Americans to access a bundled offering that includes the pharma giant’s obesity drug Wegovy and a Hims & Hers membership…
Continue Reading
What You Should Know:
– PatchMD, a pioneer in transdermal nutrient delivery, has unveiled its new GLP-1 Support Patch Collection, designed to provide essential support for individuals using GLP-1 receptor agonist medications such as Ozempic,…
Continue Reading
Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients.
Compounded GLP-1s are custom-made by compounding pharmacies and include the same…
Continue Reading
DarioHealth, a digital chronic condition management platform, announced it expanded its GLP-1 offering with prescribing capabilities, a move the company said will help it capture a larger share of the weight-loss market space.The company…
Continue Reading
The Unprecedented Rise in Medicaid’s Diabetes Drug Spending
Introduction to the Crisis
Medicaid faces a staggering projection of $29.9 billion in expenditure for type 2 diabetes and weight loss medications, according to a recent report from…
Women’s telehealth company Wisp announced a strategic partnership with food as medicine platform Nourish to allow Wisp patients to access nutrition counseling services via their health insurance or an exclusive self-pay rate The aim is…
Continue Reading
Women’s telehealth company Wisp and food as medicine platform Nourish have launched a partnership to support patients taking GLP-1s, the companies announced Wednesday. Wisp patients can now access nutrition counseling support through Nourish.
New York…
Continue Reading
What You Should Know:
– A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with…
Continue Reading
As the nation grapples with a GLP-1 shortage, Hims & Hers is looking to improve access by making compounded GLP-1s available on its platform starting at $199 a month, the company announced Monday.
The San…
Continue Reading
Direct-to-consumer virtual care company Hims & Hers is the latest digital health company to announce it will add GLP-1 medications to its offerings to assist users with weight loss management. The San Francisco-based company, which…
Continue Reading
